Pharmacovigilance activities in 55 low-and middle-income countries: A questionnaire-based analysis

Drug Safety

Volumn 33, Issue 8, 2010, Pages 689-703

  Olsson, Sten ^a   Pal, Shanthi N ^b   Stergachis, Andy ^c   Couper, Mary ^b  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adverse reaction monitoring; Pharmacovigilance.

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT SAFETY; PRIORITY JOURNAL; PUBLIC HEALTH; QUESTIONNAIRE; SOCIAL CLASS; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HUMANS; INCOME; INTERNATIONALITY; MALE; QUESTIONNAIRES; WORLD HEALTH ORGANIZATION;

EID: 77954724803     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11536390-000000000-00000     Document Type: Article

References (22)

1. Olsson S, editor. National pharmacovigilance systems. 2nd ed. Uppsala: The Uppsala Monitoring Centre, 1999
2. Ratanawijitrasin S, Wondemagegnehu E. Effective drug regulation: a multi-country study. Geneva: WHO, 2002
3. Hughes ML, Whittlesea CMC, Luscombe DK. Review of national spontaneous reporting schemes: strengths and weaknesses. Adv Drug React Toxicol Rev 2002; 21: 231-41
4. Sachdev Y. Status of adverse drug reaction monitoring and pharmacovigilance in selected countries. Indian J Pharmacol 2008; 40 Suppl. 1: S4-9
5. World Health Organization. The importance of pharmacovigilance. Geneva: WHO, 2002: 42
6. Lo Re 3rd VL, Strom BL. The role of academia and the research community in assisting the food and drug administration to ensure US drug safety. Pharmacoepidemiol Drug Saf 2007 Jul; 16 (7): 818-25
7. Biriell C, Edwards IR. Reasons for reporting adverse drug reactions: some thoughts based on an international review. Pharmacoepidemiol Drug Saf 1997; 6: 21-6
8. Bukirwa H, Nayiga S, Lubanga R, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health 2008; 13 (9): 1143-52
9. Encheva D. Spontaneous reporting and continuing medical education. Uppsala Rep 2004 Apr; 25: 10-1
10. Sevene E, Mariano A, Mehta U, et al. Spontaneous adverse drug reaction reporting in rural districts of Mozambique. Drug Saf 2008; 31 (10): 867-76
11. World Health Organization. National policy on traditional medicine and regulation of herbal medicines: report of a WHO global survey. Geneva: WHO, 2005
12. World Health Organization. WHO traditional medicine strategy: 2002-2005. Geneva: WHO, 2002
13. Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med 2004; 16 (1): 5-19
14. Australian Council for Safety and Quality in Health Care. Partnerships for health in action: promoting consumer and community involvement in healthcare improvement. Canberra (ACT): Australian Council for Safety and Quality in Health Care, 2005
15. van Grootheest K, Graaf L, Lolkje TW, et al. Consumer adverse drug reaction reporting: a new step in pharma-covigilance. Drug Saf 2003; 26 (4): 211-7
16. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance an essential tool. Geneva: WHO, 2006
17. Shin YS, Lee YW, Choi YH, et al. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. Pharmacoepidemiol Drug Saf 2009 Oct; 18 (10): 910-5
18. World Health Organization. A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva: WHO, 2007
19. Dodoo A, Adjei S, Couper M, et al. When rumours derail a mass deworming exercise. Lancet 2007; 370: 465-6
20. The Uppsala Monitoring Centre. Dialogue in pharmacovigilance: more effective communication. Uppsala: Uppsala Monitoring Centre, 2002
21. The Uppsala Monitoring Centre. Expecting the worst: anticipating, preventing and managing medicinal product crises. Uppsala: Uppsala Monitoring Centre, 2003
22. Pirmohamed M, Atuah KN, Dodoo A, et al. Pharmacovigilance in developing countries. BMJ 2007; 335: 462